Mysterious Drug-Resistant Germ Deemed An "Urgent Threat" Is

New Post Public Reply Private Reply Replies (1) Message Board
Lmcat wowhappens28 #20020
363
Mysterious Drug-Resistant Germ Deemed An "Urgent Threat" Is Quietly Sweeping The Globe
04/06/2019

Thanks to the overprescription of antimicrobial drugs and use of antifungicides in crop production, a relatively new germ that preys on people with weakened immune systems is rapidly spreading across the globe, according to the New York Times.

The infection - a fungus known as Candida auris, kills almost half of all patients who contract it within 90 days , according to the CDC - as it's impervious to most major antifungal medications.

First described in 2009 after a 70-year-old Japanese woman showed up at a Tokyo hospital with C. auris in her ear canal, the aggressive yeast infection has spread across Asia and Europe - arriving in the US by 2016.

The earliest known case in the United States involved a woman who arrived at a New York hospital on May 6, 2013, seeking care for respiratory failure. She was 61 and from the United Arab Emirates, and she died a week later, after testing positive for the fungus.
At the time, the hospital hadn’t thought much of it, but three years later, it sent the case to the C.D.C. after reading the agency’s June 2016 advisory. -NYT



"It is a creature from the black lagoon," said the CDC's Dr. Tom Chiller, who heads the fungal branch. "It bubbled up and now it is everywhere."

In the last five years alone, it it has swept through a hospital in Spain, hit a neonatal unit in Venezuela, spread throughout India, Pakistan and South Africa, and forced a prestigious British medical center to close its ICU for nearly two weeks.

By the end of June 2016, a scientific paper reported “an ongoing outbreak of 50 C. auris cases” at Royal Brompton, and the hospital took an extraordinary step: It shut down its I.C.U. for 11 days, moving intensive care patients to another floor, again with no announcement.

Days later the hospital finally acknowledged to a newspaper that it had a problem. A headline in The Daily Telegraph warned, “Intensive Care Unit Closed After Deadly New Superbug Emerges in the U.K.” (Later research said there were eventually 72 total cases, though some patients were only carriers and were not infected by the fungus.) -NYT

After C. auris reached New York, New Jersey and Illinois, the CDC added it to a list of germs deemed "urgent threats."



Last May, an elderly man who was admitted to the Brooklyn branch of Mount Sinai Hospital for abdominal surgery was found to be infected with the drug-resistant candida. He died after 90 days in the hospital, however C. auris did not according to the Times.

According to tests, the germ was everywhere in his room - to such a degree that the hospital required special cleaning equipment and had to rip out ceiling and floor tiles to get rid of it.

"Everything was positive — the walls, the bed, the doors, the curtains, the phones, the sink, the whiteboard, the poles, the pump," said Hospital president Dr. Scott Lorin. "The mattress, the bed rails, the canister holes, the window shades, the ceiling, everything in the room was positive."

glass%20slide.jpg
Dr. Shawn Lockhart, a fungal disease expert at the Centers for Disease Control, holding a microscope slide with inactive Candida auris collected from an American patient.

Why is this happening?

Simply put, fungi are evolving defenses to resist and survive modern medications.
"It’s an enormous problem," said Imperial College of London fungal epidemiology professor Matthew Fisher, who co-authored a recent scientific review on the rise of resistant fungi.
"We depend on being able to treat those patients with antifungals."

The C.D.C. investigators theorized that C. auris started in Asia and spread across the globe. But when the agency compared the entire genome of auris samples from India and Pakistan, Venezuela, South Africa and Japan, it found that its origin was not a single place, and there was not a single auris strain.
...

The genome sequencing showed that there were four distinctive versions of the fungus, with differences so profound that they suggested that these strains had diverged thousands of years ago and emerged as resistant pathogens from harmless environmental strains in four different places at the same time. -NYT

"Somehow, it made a jump almost seemingly simultaneously, and seemed to spread and it is drug resistant, which is really mind-boggling," said CDC fungal expert Dr. Snigdha Vallabhaneni.

While various theories exist as to why C. auris has made a grand entrance, Dutch microbiologist Jacques Meis believes the drug-resistant fungi are developing thanks to the heavy use of fungicides on crops.

Dr. Meis visited the C.D.C. last summer to share research and theorize that the same thing is happening with C. auris, which is also found in the soil: Azoles have created an environment so hostile that the fungi are evolving, with resistant strains surviving.

This is similar to concerns that resistant bacteria are growing because of excessive use of antibiotics in livestock for health and growth promotion. As with antibiotics in farm animals, azoles are used widely on crops. -NYT

"On everything — potatoes, beans, wheat, anything you can think of, tomatoes, onions," said Dr. Johanna Rodes, an infectious disease expert at Imperial College London.

"We are driving this with the use of antifungicides on crops."

Keeping it quiet

In 2015, Dr. Rhodes received a panicked call from the Royal Brompton Hospital medical research center outside of London, where C. auris had taken root months earlier. The hospital had no idea how to get rid of it.

joanna.jpg
Dr. Johanna Rhodes, an infectious disease expert at Imperial College, London.
"We have no idea where it’s coming from. We’ve never heard of it. It’s just spread like wildfire," Rhodes was told, before she helped them clean it up. Under her direction, hospital workers used a special aerosol devices to spray hydrogen peroxide around a room which housed a patient with the germ - with the theory being that the vapor would permeate the entire room.

After one week of saturating the room, they put a "settle plate" in the middle of it with a gel at the bottom that would allow any remaining microbes to grow.

Only one grew back; C. auris. And officials were scrambling to keep a lid on it.

It was spreading, but word of it was not. The hospital, a specialty lung and heart center that draws wealthy patients from the Middle East and around Europe, alerted the British government and told infected patients, but made no public announcement.

“There was no need to put out a news release during the outbreak,” said Oliver Wilkinson, a spokesman for the hospital.

This hushed panic is playing out in hospitals around the world. Individual institutions and national, state and local governments have been reluctant to publicize outbreaks of resistant infections, arguing there is no point in scaring patients — or prospective ones. -NYT

And while the Brompton Hospital case did make headlines, the issue remained largely out of the spotlight internationally - despite an even larger outbreak in Valencia, Spain occurring at virtually the same time at the 992-bed Hospital Universitari i Politècnic La Fe.

Unknown to the public or unaffected patients, 372 people had become "colonized" with the germ - meaning it was on their bodies but they had not yet contracted it. Of those, 85 patients developed bloodstream infections, and 41% of those died within 30 days.

And while other prominent strains of Candida have not developed significant resistance to drugs, over 90% of C. auris infections are resistant to at least one drug, while 30% are resistant to two or more drugs.

According to Connecticut's deputy state epidemiologist Dr. Lynn Sosa, C. auris is now "the top" threat among resident infections.

"It’s pretty much unbeatable and difficult to identity."

https://www.zerohedge.com/news/2019-04-06/mys...ping-globe


Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 0

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 206

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 0

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 64

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 50

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 208

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 79

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 287

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 7

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 124

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading

Top 5 Most Recently Viewed Articles

Red Cat Holdings Faces Class Action Lawsuit from Investors

Updated Category News Views 209

Overview of the Class Action Against Red Cat Holdings Pomerantz LLP has announced that a class action lawsuit has been initiated against Red Cat Holdings, Inc. (RCAT) and certain officers due to allegations of misconduct. The legal action is filed in the United States District Court for the District of New Jersey. This lawsuit represents a class of individuals or entities...

Continue Reading
IPVanish: The Ultimate Solution for Cloud Storage Security

Updated Category News Views 129

IPVanish: Leading the Charge in Cloud Security As more individuals and businesses migrate to the cloud, the urgency for secure storage solutions has skyrocketed. IPVanish has stepped up to become a standout player in this landscape, recognized for its outstanding cloud access tools and strong privacy measures. Transformation into a Comprehensive Security Platform...

Continue Reading
Runway Growth Capital Bolsters Leadership with Rovner

Updated Category News Views 11

A New Era for Runway Growth Capital Alright folks, here's the scoop for anyone tracking the moves in the growth lending space: Michael Rovner, with his hefty 30-year career in the financial sector, is now taking on the role of Co-Chief Executive Officer and Co-Chief Investment Officer at Runway Growth Capital. This guy's a veteran, no doubt, having navigated the overlaps...

Continue Reading
Investors Anticipate Earnings from Booz Allen Hamilton Soon

Updated Category News Views 134

Market Expectations for Booz Allen Hamilton's Earnings Booz Allen Hamilton (NYSE: BAH) is set to unveil its quarterly earnings soon, and it's important for investors to be well-prepared. Analysts anticipate an earnings per share (EPS) of $1.51, a key figure to watch as it could impact stock sentiment significantly. Performance Insights and Analyst Predictions The hope...

Continue Reading
USD/JPY Holds Steady Amid Economic Shifts and Data Releases

Updated Category News Views 124

USD/JPY Stabilizes After Inflation Adjustments The USD/JPY currency pair has recently stabilized after a brief drop below the key level of 141.77. This dip happened just before the US Consumer Price Index (CPI) was announced, revealing an inflation rate of 2.5%. Following this data release, the currency pair started to rebound, thanks in part to a slight increase in US...

Continue Reading